This website is intended for healthcare professionals only

Trending Topic

Denver aad 2026
5 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Join us as leading experts discuss key data and perspectives from the late-breaking sessions at this year’s AAD meeting This March, experts from around the world gathered in Denver, Colorado, for the 2026 American Academy of Dermatology (AAD) Annual Meeting. This year’s meeting showcased a strong pipeline of innovation in inflammatory and immune-mediated skin diseases, […]

Pediatric Skin Conditions

An Introduction to Pediatric Skin Conditions

Supported by:
US Partner
touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Your clinical career is shaped not only by what you know, but by who helps you navigate what comes next. Join us for the final episode in our LEADderm mini-series exploring non-clinical skills that can help you thrive in your ...

8 defining developments in dermatology in 2025
Mark CompleteCompleted
BookmarkBookmarked
Raj Chovatiya, Tiago Torres, Yi-Kui Xiang

As 2025 draws to a close, it is clear that the past year has brought notable shifts across dermatology. To reflect on the developments that stood out most, members of our editorial board and recipients of our 2025 Future Leaders in Dermatology award share their perspectives, drawing on experience across subspecialties, regions and stages of career.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode of Visionary Voices, we welcome Associate Professor Grace Vincent from CQUniversity’s Appleton Institute. A leading expert on sleep and shift work, Grace explores how disrupted sleep affects physician health in both the short and long term, as well as its impact on safety and performance. We also discuss what this means for patient outcomes and share practical strategies to manage sleep loss.

atopic eczema
Mark CompleteCompleted
BookmarkBookmarked

The EADV 2025 Congress in Paris showcased the latest research and treatment advances in dermatology. To highlight the most important updates in both paediatric and adult atopic dermatitis, we spoke with Professor Carsten Flohr, a leading expert from London, UK.

Epidermal differentiation disorders
Mark CompleteCompleted
BookmarkBookmarked
Coverage from: EADV 2025
Antoni Gostyński

Epidermal differentiation disorders (EDDs) are a group of inherited skin conditions caused by disruptions in epidermal development. In recent years, the field has seen major progress, with significant updates to nomenclature, classification and their management. To gain deeper insight into these developments, we spoke with Dr Antoni Gostyński (Maastricht, Netherlands), who co-chaired the EADV 2025 session ‘Epidermal Differentiation Disorders (EDDs) Group: From Genes to Clinics – The Truth About EDDs in 90 Minutes’.

childhood food allergies
touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we speak with leading paediatric allergist Prof. Helen Brough to explore the key factors behind why some children develop allergies to foods such as peanuts, and what we can do to help prevent them. We also examine the latest developments in managing food allergies and the innovations on the horizon that could transform how we treat them.

15 minutes
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

Expert insights on referral, risk stratification and treatment for patients with infantile haemangiomas.

Endorsed by the Pediatric Dermatology Research Alliance (PeDRA).

touchDERMATOLOGY Future Leaders 2025
Mark CompleteCompleted
BookmarkBookmarked

This year, we are celebrating our inaugural touchDERMATOLOGY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform dermatology in the years to come. Representing a diverse range of expertise from across the globe, these highly accomplished clinicians are among the brightest minds shaping the future of dermatology. We had the pleasure of learning about their unique career journeys, motivations, and the inspirations that have guided their paths. They also shared their perspectives on the most exciting developments in dermatology today, along with their hopes for the future of the field. Congratulations to all our touchDERMATOLOGY Future Leaders, and thank you for sharing your stories, insights and ambitions with us.

Burnout
touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

Visionary Voices
touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

With a career that spans continents, Prof. Dedee Murrell stands out as a global leader in dermatology and a passionate advocate for women in medicine. In this episode, we sit down together to explore her inspiring journey—from her early years in the UK and medical training in the USA to pioneering therapies for some of dermatology’s rarest and underserved conditions in Australia. We also reflect on her recent MDS Lifetime Achievement Award and discuss the value of mentorship, strategies for advancing a career in dermatology and academic medicine, and how to stay at the cutting edge of medical innovation.

Early-onset atopic dermatitis
Mark CompleteCompleted
BookmarkBookmarked

Atopic dermatitis (AD) is a chronic inflammatory skin condition affecting approximately 10–30% of children worldwide. Early-onset AD, which often emerges by age two, is associated with a higher risk of developing other allergic diseases such as asthma and food allergies. Beyond its physical burden, AD significantly impacts patients and their families, contributing to sleep disturbances, emotional distress, financial burdens, and social challenges.

33 minutes
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

An expert in paediatric dermatology provides guidance on managing patients with epidermolysis bullosa

Layer of cells, human skin cells, medical illustration
Mark CompleteCompleted
BookmarkBookmarked

In an encouraging development for children with severe atopic dermatitis (AD), dupilumab, an interleukin-4 (IL-4) receptor alpha antagonist, has shown evidence of improving height outcomes. According to new findings presented by Prof. Alan Irvine (Trinity College Dublin, Ireland) at the 2024 ...

39 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION
Prof. Dr. med. Diamant Thaçi, Dr Benjamin Ungar

Watch expert dermatologists discuss the management of moderate-to-severe AD in children and adolescents.

52 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION
Prof. Dr Vito Sabato, Dr Sigurd Broesby-Olsen, Prof. Prithviraj Bose

Multidisciplinary experts discuss the diagnosis and management of patients with systemic mastocytosis.

38 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION
Dr Elaine Siegfried, Assist. Prof. Nives Pustišek, Prof. Andreas Wollenberg

Watch three experts discuss how they manage moderate-to-severe atopic dermatitis in children.

Developed by Touch
Coverage from: AAD 2023

Dupilumab is a monoclonal antibody approved for use in patients with atopic dermatitis that is not well controlled with topical treatments, or who are unable to use topical treatments. It was a pleasure to talk with Prof Amy Paller (Northwestern University Feinberg School of Medicine; Lurie Children's Hospital of Chicago, Chicago, IL, USA) about the key takeaways from the LIBERTY AD PRESCHOOL and the ongoing open-label extension trial, which is investigating the safety of dupilumab treatment in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis.

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritic skin lesions.1 It is the most common chronic inflammatory skin disease in children.1 Dupilumab (Regeneron Pharmaceuticals and Sanofi Genzyme) is a monoclonal antibody and interleukin-4 (IL-4) receptor alpha ...

Load More...
Close Popup